These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 18331662)

  • 1. The nutraceutical role of the Phaseolus vulgaris alpha-amylase inhibitor.
    Obiro WC; Zhang T; Jiang B
    Br J Nutr; 2008 Jul; 100(1):1-12. PubMed ID: 18331662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of alpha-amylase inhibitor activity of phaseolamin from kidney bean (Phaseolus vulgaris) in dietary supplements by HPAEC-PAD.
    Mosca M; Boniglia C; Carratù B; Giammarioli S; Nera V; Sanzini E
    Anal Chim Acta; 2008 Jun; 617(1-2):192-5. PubMed ID: 18486657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nutraceutical resources for diabetes prevention--an update.
    McCarty MF
    Med Hypotheses; 2005; 64(1):151-8. PubMed ID: 15533633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxicity studies of Blockal, a dietary supplement containing Phase 2 Starch Neutralizer (Phase 2), a standardized extract of the common white kidney bean (Phaseolus vulgaris).
    Chokshi D
    Int J Toxicol; 2006; 25(5):361-71. PubMed ID: 16940008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isolation and activity of an alpha-amylase inhibitor from white kidney beans.
    Zhang XQ; Yang MY; Ma Y; Tian J; Song JR
    Yao Xue Xue Bao; 2007 Dec; 42(12):1282-7. PubMed ID: 18338641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Common bean (Phaseolus vulgaris L.) α-amylase inhibitors as safe nutraceutical strategy against diabetes and obesity: An update review.
    Peddio S; Padiglia A; Cannea FB; Crnjar R; Zam W; Sharifi-Rad J; Rescigno A; Zucca P
    Phytother Res; 2022 Jul; 36(7):2803-2823. PubMed ID: 35485365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beans and diabetes: Phaseolus vulgaris preparations as antihyperglycemic agents.
    Helmstädter A
    J Med Food; 2010 Apr; 13(2):251-4. PubMed ID: 20132042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitory specificity and insecticidal selectivity of alpha-amylase inhibitor from Phaseolus vulgaris.
    Kluh I; Horn M; Hýblová J; Hubert J; Dolecková-Maresová L; Voburka Z; Kudlíková I; Kocourek F; Mares M
    Phytochemistry; 2005 Jan; 66(1):31-9. PubMed ID: 15649508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Molecular targets for new drug discovery to treat type 2 diabetes and obesity].
    Bastarrachea RA; Montero JC; Saavedra-Gajardo I; Cerda-Flores R; Machado-Domínguez A; Comuzzie AG
    Rev Med Chil; 2008 Jan; 136(1):107-17. PubMed ID: 18483661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-hydroxypropylated tapioca starch improves insulin resistance in genetically diabetic KKAy mice.
    Kato R; Tachibe M; Sugano S; Kishida T; Ebihara K
    J Food Sci; 2009 Apr; 74(3):H89-96. PubMed ID: 19397723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neferine enhances insulin sensitivity in insulin resistant rats.
    Pan Y; Cai B; Wang K; Wang S; Zhou S; Yu X; Xu B; Chen L
    J Ethnopharmacol; 2009 Jul; 124(1):98-102. PubMed ID: 19527823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of decreasing intraluminal amylase activity on starch digestion and postprandial gastrointestinal function in humans.
    Layer P; Zinsmeister AR; DiMagno EP
    Gastroenterology; 1986 Jul; 91(1):41-8. PubMed ID: 2423408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DGAT1 inhibitors as anti-obesity and anti-diabetic agents.
    Birch AM; Buckett LK; Turnbull AV
    Curr Opin Drug Discov Devel; 2010 Jul; 13(4):489-96. PubMed ID: 20597032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of alpha-amylase inhibitors from Phaseolus coccineus on digestive alpha-amylases of the coffee berry borer.
    Valencia-Jiménez A; Arboleda Valencia JW; Grossi-De-Sá MF
    J Agric Food Chem; 2008 Apr; 56(7):2315-20. PubMed ID: 18321052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of metformin for weight management in patients without type 2 diabetes.
    Desilets AR; Dhakal-Karki S; Dunican KC
    Ann Pharmacother; 2008 Jun; 42(6):817-26. PubMed ID: 18477733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
    Resmini E; Minuto F; Colao A; Ferone D
    Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical therapy for the patient with obesity.
    Bray GA; Ryan DH
    Circulation; 2012 Apr; 125(13):1695-703. PubMed ID: 22474312
    [No Abstract]   [Full Text] [Related]  

  • 18. Antiobesity effects and improvement of insulin sensitivity by 1-deoxynojirimycin in animal models.
    Kong WH; Oh SH; Ahn YR; Kim KW; Kim JH; Seo SW
    J Agric Food Chem; 2008 Apr; 56(8):2613-9. PubMed ID: 18363357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Energy balance, physical activity, and cancer risk.
    Fair AM; Montgomery K
    Methods Mol Biol; 2009; 472():57-88. PubMed ID: 19107429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FGF21: a novel prospect for the treatment of metabolic diseases.
    Kharitonenkov A; Shanafelt AB
    Curr Opin Investig Drugs; 2009 Apr; 10(4):359-64. PubMed ID: 19337957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.